These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9487605)
21. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Roach P; Trautmann M; Arora V; Sun B; Anderson JH Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421 [TBL] [Abstract][Full Text] [Related]
22. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682 [TBL] [Abstract][Full Text] [Related]
23. Insulin lispro (Humalog), the first marketed insulin analogue: indications, contraindications and need for further study. Puttagunta AL; Toth EL CMAJ; 1998 Feb; 158(4):506-11. PubMed ID: 9627564 [TBL] [Abstract][Full Text] [Related]
24. Insulin lispro in CSII: results of a double-blind crossover study. Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100 [TBL] [Abstract][Full Text] [Related]
25. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069 [TBL] [Abstract][Full Text] [Related]
26. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455 [TBL] [Abstract][Full Text] [Related]
27. [Two consecutive pregnancies in a type 1 diabetic under treatment with insulin Lispro]. Ahlbach S; Usadel KH; Badenhoop K Med Klin (Munich); 2003 Apr; 98(5):245-7. PubMed ID: 12721667 [TBL] [Abstract][Full Text] [Related]
28. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242 [TBL] [Abstract][Full Text] [Related]
29. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088 [TBL] [Abstract][Full Text] [Related]
30. Lispro insulin as premeal therapy in type 1 diabetes: comparison with Humulin R. Daniels AR; Bruce R; McGregor L N Z Med J; 1997 Nov; 110(1056):435-8. PubMed ID: 9418839 [TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of insulin lispro in patients with diabetes mellitus. Cheţa D; Străchinariu R; Trifan E; Nicolau A; Ionescu-Tîrgovişte C; Georgescu M; Ghenof M; Mincu I; Uţă D; Ristic S Rom J Intern Med; 1998; 36(1-2):85-96. PubMed ID: 10660973 [TBL] [Abstract][Full Text] [Related]
32. Impact of insulin lispro on HbA1c values in insulin pump users. Garg SK; Anderson JH; Gerard LA; Mackenzie TA; Gottlieb PA; Jennings MK; Chase HP Diabetes Obes Metab; 2000 Oct; 2(5):307-11. PubMed ID: 11225746 [TBL] [Abstract][Full Text] [Related]
33. Insulin lispro: its role in the treatment of diabetes mellitus. Campbell RK; Campbell LK; White JR Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409 [TBL] [Abstract][Full Text] [Related]
34. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Anderson JH; Brunelle RL; Koivisto VA; Pfützner A; Trautmann ME; Vignati L; DiMarchi R Diabetes; 1997 Feb; 46(2):265-70. PubMed ID: 9000704 [TBL] [Abstract][Full Text] [Related]
35. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659 [TBL] [Abstract][Full Text] [Related]
36. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? Schmauss S; König A; Landgraf R Diabet Med; 1998 Mar; 15(3):247-9. PubMed ID: 9545126 [TBL] [Abstract][Full Text] [Related]
37. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Ahmed AB; Home PD Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967 [TBL] [Abstract][Full Text] [Related]
38. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Holcombe JH; Zalani S; Arora VK; Mast CJ; Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407 [TBL] [Abstract][Full Text] [Related]
39. Lispro insulin treatment in comparison with regular human insulin in type 2 diabetic patients living in nursing homes. Velussi M Diabetes Nutr Metab; 2002 Apr; 15(2):96-100. PubMed ID: 12059098 [TBL] [Abstract][Full Text] [Related]
40. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Ahmed AB; Home PD Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]